

**International Conference**  
**“CLINICAL GENETICS OF CANCER 2018”**  
**Szczecin, 11-12 October 2018**  
**(Pomeranian University Medical in Szczecin, Rybacka 1)**

**Thursday (11 October 2018)**

|               |  |
|---------------|--|
| 9:00 - 9:15   | Conference opening   |
| 9:15 - 9:40   | Paradigm shifts in gene identification: genome-wide association or sequencing? (K. Hemminki, Germany)  |
| 9:40 - 10:05  | Search for new genomic changes associated with high risk of cancer. (C. Cybulski, Poland)  |
| 10:05 - 10:30 | Cancer genetic testing and counseling on the move. (R. Sijmons, Netherlands)   |
| 10:30 - 11:00 | <b>Coffee break</b>  |
| 11:00 - 11:25 | A genetic variant in telomerase reverse transcriptase (TERT) modifies cancer risk in Lynch syndrome patients harbouring pathogenic MSH2 mutations. (R. Scott, Australia) |
| 11:25 - 11:45 | Mutations of genes predisposing to occurrence of intestinal polyposis in Poland. (A. Pławski, Poland)  |
| 11:45 - 12:05 | Association between mutations in genes from NGS multi-gene panels and breast and ovarian cancer risk. (M. Suszyńska, Poland)   |
| 12:05 - 12:25 | Spectrum of BRCA1 / BRCA2 mutations - results of NGS analysis of patients from International Hereditary Cancer Center (IHCC). (A. Jakubowska, Poland)                    |
| 12:25 - 12:40 | Constitutional methylation of BRCA1 gene and breast cancer risk. (K. Prajzendanc, Poland)  |
| 12:40 - 12:55 | BRCA1/2, CHEK2, PALB2 and RAD51C mutations in ovarian cancer patients from Polish population. (Łukomska, Poland)   |
| 12:55 - 13:10 | The presence of NOD2 mutation in younger breast cancer patients – single center experiences. (J. Huszno, Poland)   |
| 13:10 - 14:00 | <b>Lunch</b>   |

|                      |  |
|----------------------|--|
| 14:00 - 14:20        | Clinical and molecular aspects of hereditary breast cancer diagnosis and management: PALB2 and RECQL epidemiology in Latvia, Manchester scoring system and contralateral breast cancer risk reduction. (A. Irmejs, Latvia) |
| 14:20 - 14:35        | BRCA1/2 mutations are not a common cause of malignant melanoma in the Polish population. (T. Dębniak, Poland)  |
| 14:35 - 14:45        | PALB2 mutation in a woman with breast cancer: A case report. (M. Lisik, Poland)  |
| 14:45 - 15:05        | BRCA1 – related multiple primary cancers in Belarus (A. Savanevich, Belarus)   |
| 15:05 - 15:20        | CHEK2 c.444+1G>A variant and papillary thyroid cancer – own study and meta-analysis. (D. Kula, Poland)   |
| 15:20 - 15:35        | Evaluation of the effectiveness of recruitment methods for prophylactic examinations in groups of high-risk cancer patients. (A. Galor, Poland)  |
| <b>15:35 - 16:00</b> | <b>Coffee break</b>  |
| 16:00 - 16:25        | BRCA1-driven ovarian cancer: drugs sensitivity and pattern of relapses. (E. Ilyanitov, Russia)   |
| 16:25 - 16:45        | Long-term survival of invasive ovarian cancer associated with BRCA1- 4153delA mutation in Lithuanian population. (P. Elsakov, Lithuania)   |
| 16:45 - 17:00        | Serum and blood trace metal levels as prognostic marker of survival in laryngeal cancer. (Jakub Lubiński, Poland)  |
| 17:00 - 17:15        | Does the selenium level affect overall survival in lung cancer? (S. Pietrzak, Poland)  |
| 17:15 - 17:30        | Zinc as marker of cancer risk. (K. Białkowska, Poland)   |
| 17:30 - 17:45        | Blood copper (Cu) level as a marker of cancer risk. (M. Muszyńska, Poland)   |
| 17:45 - 18:00        | Blood cadmium (Cd) level as a marker of cancer risk. (W. Marciniak, Poland)  |
| 18:00 - 18:15        | Arsenic as a marker of cancer risk. (R. Derkacz, Poland)   |
| 18:15 - 18:30        | SELINA – clinical trial on lowering the risk of malignancies by optimizing selenium levels in females from families with hereditary breast cancer. (Jan Lubiński, Poland)  |
| 18:30 - 18:45        | Wręczenie nagród w konkursie „Drzewo genealogiczne zdrowia mojej rodziny”  |
| <b>18:45</b>         | <b>Dinner</b>  |

## **Friday (12 October 2018)**

|                      |   |
|----------------------|---|
| 8:30 - 8:50          | Próby kliniczne u nosicielek mutacji w genie BRCA1. (T. Huzarski, Poland)   |
| 8:50 - 9:10          | Zasady prowadzenia pacjentek z mutacją genu BRCA1. (J. Gronwald, Poland)  |
| 9:10 - 9:30          | Czy sztuczna inteligencja zastąpi diagnostę i zwiększy wykonanie badań cytologicznych w ramach profilaktyki raka szyjki macicy? (T. Włodarczyk, Poland) |
| 9:30 - 10:30         | Prezentacje przypadków cz. I  |
| <b>10:30 - 11:00</b> | <b>Coffee break</b>   |
| 11:00 - 12:00        | Prezentacje przypadków cz. II   |
| 12:00 - 13:00        | Zebranie Sekcji Genetyki Klinicznej Nowotworów Polskiego Towarzystwa Genetyki Człowieka   |
| 13:00                | <b>Closing</b><br><b>Lunch</b>  |

## **Honorary patronage / Honorowy patronat:**

**Marshal of the Zachodniopomorskie Voivodeship /  
Marszałek Województwa Zachodniopomorskiego, Olgierd Geblewicz**



PATRONAT HONOROWY  
MARSZAŁKA WOJEWÓDZTWA  
ZACHODNIOPOMORSKIEGO  
OLGIERDA GEBLEWICZA

**Rector of Pomeranian Medical University in Szczecin /  
J.M. Rektor PUM, prof. dr hab. n. med. Bogusław Machaliński**



Patronat Honorowy Rektora  
Pomorskiego Uniwersytetu Medycznego  
w Szczecinie

**Regional Medical Chaber in Szczecin  
Okręgowa Izba Lekarska w Szczecinie**



**Sponsors / Sponsorzy:**



Ministerstwo Nauki  
i Szkolnictwa Wyższego



Marszałek Województwa  
Zachodniopomorskiego



**Organisers / organizatorzy:**


**National Association for the Support of Families with Inherited Predisposition to Cancer /  
Ogólnopolskie Stowarzyszenie Wspierania Rodzin z Predyspozycjami do Nowotworów  
Dziedzicznych**



Ogólnopolskie  
Stowarzyszenie  
Wspierania Rodzin  
z Predyspozycjami  
do Nowotworów  
Dziedzicznych

**Zakład Genetyki i Patomorfologii PUM w Szczecinie**

**International Hereditary Cancer Center of Pomeranian Medical University in Szczecin /  
Międzynarodowe Centrum Nowotworów Dziedzicznych Pomorskiego Uniwersytetu  
Medycznego w Szczecinie**



**European  
Reference  
Network**  
for rare or low prevalence  
complex diseases

❖ **Network**  
Genetic Tumour Risk  
Syndromes (ERN GENTURIS)

● **Member**  
University Clinical  
Hospital n°1, Pomeranian  
Medical University in  
Szczecin — Poland



[www.genturis.eu](http://www.genturis.eu)

**Section of Clinical Genetics of Cancer of Polish Society of Human Genetics  
Sekcja Genetyki Klinicznej Nowotworów Polskiego Towarzystwa Genetyki Człowieka**